Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study on the Safety and Effectiveness of SXR1096 Cream for Patients with Netherton Syndrome

Verified siteInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying Netherton syndrome, a rare genetic skin disorder. The treatment being tested is a cream called SXR1096, which is applied directly to the skin. This cream is designed to target specific proteins in the skin that are involved in the symptoms of Netherton syndrome. The purpose of the study is to evaluate the safety and effectiveness of the SXR1096 cream compared to a placebo in patients with this condition.

The study will involve participants using the cream for a period of time, with regular check-ups to monitor their health and the condition of their skin. Participants will apply the cream to affected areas of their skin, and researchers will assess any changes in their symptoms. The study aims to determine if the cream can improve the skin condition and reduce symptoms such as redness, scaling, and itching.

Throughout the study, participants will be closely monitored for any side effects or changes in their health. The study will also measure various aspects of skin health, such as the severity of skin symptoms and the skin's moisture levels. This research is important for understanding how SXR1096 cream can help people with Netherton syndrome and potentially improve their quality of life.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial treatment phase

    The study involves the application of a cream containing the active substance sxr1096. This cream is applied topically, meaning it is used directly on the skin.

    The treatment is designed for individuals diagnosed with Netherton syndrome, a condition affecting the skin.

  2. Step 2

    Application of cream

    The cream is applied to specific areas of the skin. Each target area is approximately 9% of the body surface area, similar to the size of one arm.

    The application is done as instructed by the study guidelines, ensuring consistent use throughout the trial period.

  3. Step 3

    Monitoring and assessment

    Regular assessments are conducted to monitor safety and effectiveness. This includes checking for any adverse effects and evaluating the condition of the skin.

    The primary focus is on changes in the skin's appearance and condition, using a scoring system to measure improvements or changes.

  4. Step 4

    Completion of treatment

    The study aims to conclude by April 30, 2024. Participants will continue to apply the cream and attend scheduled assessments until the end of the trial.

    Final evaluations will be conducted to determine the overall effectiveness and safety of the treatment.

Who can join the trial?

19 criteria

  • Patients must be male or female, aged 18 to 65 years. Adolescents aged 12-17 years can join only after an initial group of 5 adult patients have been treated for at least 7 days.
  • Patients must agree to provide written informed consent. For adolescents, a legal guardian must explain the consent information to ensure understanding.
  • Patients must have a clinical diagnosis of **Netherton syndrome (NS)**, meeting at least 3 of the following criteria:
    • **Neonatal erythroderma**: A skin condition present at birth.
    • **Bamboo hair** and/or **alopecia**: Hair that looks like bamboo and/or hair loss.
    • **Chronic atopy**: Long-term conditions like food allergy, asthma, rhino conjunctivitis, and/or eczema for at least 2 years.
    • **Ichthyosis linearis circumflexa**: A specific skin condition.
    • Patients must be willing and able to understand and follow study requirements, apply the medication as instructed, and complete the study.
    • Patients must have absent **LEKTI** on a skin biopsy test and/or a confirmed mutation in the **SPINK5 gene**.
    • NS must affect at least 20% of the patient's body surface area at both the screening and baseline visits.
    • The **Investigator Global Assessment (IGA)** score for two areas to be treated must be 3 or higher, indicating moderate or severe condition. Each target area should be about 9% of the body surface area, similar to the size of one arm.
    • Females who can have children must either commit to true abstinence (not having heterosexual intercourse) during the trial or use a highly effective method of contraception throughout the study and for 4 weeks after the last study drug application. This also applies to prepubertal females who start menstruating during the study. Acceptable methods include:
      • Progestogen-only hormonal contraception (oral, transdermal, injectable, or implantable) that stops ovulation.
      • Combined hormonal contraception (containing estrogen and progestogen) taken orally or transdermally.
      • Injectable or implanted hormonal contraception.
      • Intrauterine devices or hormone-releasing systems.
      • Bilateral tubal ligation or tube insert (like the Essure system) done at least 3 months before the study.
      • Partner's vasectomy, confirmed to be the only sexual partner, done at least 3 months before the study with confirmed success.
      • Females who cannot have children must meet one of the following criteria:
        • No menstrual bleeding for 1 year before screening without any other medical reason.
        • Documented hysterectomy, bilateral salpingectomy, or bilateral oophorectomy done at least 3 months before screening.
        • For adolescents not yet post-pubertal, eligibility requires evaluation by a qualified medical practitioner using an acceptable sexual maturity rating scale (e.g., Tanner).

Who cannot join the trial?

3 criteria

  • Patients who are not diagnosed with Netherton syndrome (NS) cannot participate. Netherton syndrome is a rare genetic skin disorder.
  • Patients who are younger than 3 years old cannot participate.
  • Patients who are part of a vulnerable population cannot participate. A vulnerable population includes groups who may have limited ability to protect their own interests.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

SXR1096 Cream is a topical medication being tested for its safety and effectiveness in treating Netherton syndrome, a rare genetic skin disorder. This cream is applied directly to the skin and is being studied to see if it can help improve the symptoms associated with this condition, such as skin redness, scaling, and irritation. The trial aims to determine if this new treatment can provide relief for patients suffering from Netherton syndrome.

What is already known about the treatment

SXR1096 – This medication is administered as a topical cream, applied directly to the skin. It is currently in the early stages of clinical trials, specifically a phase I/II study, to assess its safety and effectiveness for treating Netherton syndrome, a rare genetic skin disorder. The main therapeutic indication for SXR1096 is to alleviate symptoms associated with Netherton syndrome. At the molecular level, the mechanism of action involves modulating specific pathways in the skin to reduce inflammation and improve skin barrier function. SXR1096 is classified pharmacologically as a dermatological agent.

Investigated diseases

Netherton Syndrome – Netherton Syndrome is a rare genetic disorder that primarily affects the skin, hair, and immune system. It is characterized by red, scaly skin, often present from birth, and a condition known as ichthyosis linearis circumflexa, which involves circular, scaly patches. Individuals with this syndrome may also have fragile hair that breaks easily, known as trichorrhexis invaginata or "bamboo hair." The skin issues can lead to increased susceptibility to infections and may cause discomfort due to itching. The condition is caused by mutations in the SPINK5 gene, which affects the skin's protective barrier. Symptoms can vary in severity and may change over time.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase I/IITrial ID2023-507743-11-00Protocol codeSXR001Estimated enrolment24 patientsSponsorSixera Pharma AB

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.